{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:00:11Z","timestamp":1790265611745,"version":"4.1.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001582"],"award-info":[{"award-number":["MOH-001582"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-001793"],"award-info":[{"award-number":["MOH-001793"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02787-3","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:44:29Z","timestamp":1789134269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of novel paracrine therapeutic targets in peritoneal metastases through integrative proteotranscriptomic analysis of ascites"],"prefix":"10.1186","volume":"25","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Yieh Lin","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Jun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu Xuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Hendrikson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey Wee-Shan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weigang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinoth Kumar","family":"Rethineswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolynn Zu Lin","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying En","family":"Quek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre Jing Yuen","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionicca","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oris Wanyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Rajesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tun Kiat","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bavani","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Yee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Chun Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vairavan","family":"Lakshmanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Brian","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagalakshmi","family":"Jegannathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig Ryan","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen Wei","family":"Neo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Yen","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R. H.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ying Joey","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lit-Hsin","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanqi","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony Kiat Hon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Chau Hsien","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christabel Jing Zhi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pik Eu Jason","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kim-Jun Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiang Keat","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravichandran","family":"Nadarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze Tein","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieera Madan","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza Li Shan","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenny Zhuoran","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy Bok Yan","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khay Guan","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene Si Min","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin Jin","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claramae Shulyn","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin Tean","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain Beehuat","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Yeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Yongsheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiannan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Ann Johnny","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Singapore Peritoneal Oncology Study (SPOS) Group and Singapore Gastric Cancer Consortium (SGCC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2787_CR1","unstructured":"Desai JP, Moustarah F. Peritoneal Metastasis. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541114\/. Accessed 30 July 2024. Cited 30 July 2024."},{"key":"2787_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3322\/caac.21749","volume":"73","author":"JM Foster","year":"2023","unstructured":"Foster JM, Zhang C, Rehman S, Sharma P, Alexander HR. The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. CA Cancer J Clin. 2023;73:49\u201371. https:\/\/doi.org\/10.3322\/caac.21749.","journal-title":"CA Cancer J Clin"},{"key":"2787_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"Cancer J Clin"},{"key":"2787_CR4","doi-asserted-by":"publisher","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","volume":"19","author":"F Coccolini","year":"2013","unstructured":"Coccolini F, Gheza F, Lotti M, Virz\u00ec S, Iusco D, Ghermandi C, et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19:6979\u201394. https:\/\/doi.org\/10.3748\/wjg.v19.i41.6979.","journal-title":"World J Gastroenterol"},{"key":"2787_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","volume":"27","author":"D Elias","year":"2009","unstructured":"Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe J-M, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681\u20135. https:\/\/doi.org\/10.1200\/JCO.2008.19.7160.","journal-title":"J Clin Oncol"},{"key":"2787_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1200\/JCO.2023.41.4_suppl.455","volume":"41","author":"YX Gwee","year":"2023","unstructured":"Gwee YX, Chia D, Provenzano L, Lonardi S, Conca V, Cremolini C, et al. Malignant ascites as a marker of peritoneal carcinomatosis burden in patients with colorectal and gastroesophageal cancer. JCO Wolters Kluwer. 2023;41:455\u2013455. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.455.","journal-title":"JCO Wolters Kluwer"},{"key":"2787_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","volume":"4","author":"SL Sangisetty","year":"2012","unstructured":"Sangisetty SL, Miner TJ. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4:87\u201395. https:\/\/doi.org\/10.4240\/wjgs.v4.i4.87.","journal-title":"World J Gastrointest Surg"},{"key":"2787_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3978\/j.issn.2078-6891.2012.053","volume":"4","author":"Y Zhu","year":"2013","unstructured":"Zhu Y, Hanna N, Boutros C, Alexander HR. Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases. J Gastrointest Oncol. 2013;4:62\u201371. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2012.053.","journal-title":"J Gastrointest Oncol"},{"key":"2787_CR9","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 3.2024 - July 15, 2024. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf. Accessed 27 Jan 2025. Cited 27 Jan 2025."},{"key":"2787_CR10","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Gastric Cancer Version 5.2024 - December 20, 2024. 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf. Accessed 27 Jan 2025. Cited 27 Jan 2025."},{"key":"2787_CR11","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCS Guidelines\u00ae) Colon Cancer Version 6.2024 - January 17, 2025. 2025 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed 27 Jan 2025. Cited 27 2025."},{"key":"2787_CR12","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Mesothelioma: Peritoneal Version 2.2025. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/meso_peritoneal.pdf. Accessed 27 Jan 2025.\u00a0Cited 27 Jan\u00a0 2025."},{"key":"2787_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1245\/s10434-018-6860-4","volume":"26","author":"Y Feferman","year":"2019","unstructured":"Feferman Y, Solomon D, Bhagwandin S, Kim J, Aycart SN, Feingold D, et al. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience. Ann Surg Oncol. 2019;26:482\u20139. https:\/\/doi.org\/10.1245\/s10434-018-6860-4.","journal-title":"Ann Surg Oncol"},{"key":"2787_CR14","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1245\/s10434-018-6539-x","volume":"25","author":"NR Sluiter","year":"2018","unstructured":"Sluiter NR, Rovers KP, Salhi Y, Vlek SL, Coup\u00e9 VMH, Verheul HMW, et al. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC. Ann Surg Oncol. 2018;25:2347\u201356. https:\/\/doi.org\/10.1245\/s10434-018-6539-x.","journal-title":"Ann Surg Oncol"},{"key":"2787_CR15","doi-asserted-by":"publisher","first-page":"e034508","DOI":"10.1136\/bmjopen-2019-034508","volume":"9","author":"NL de Boer","year":"2019","unstructured":"de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Diepeveen M, van Meerten E, van Eerden RAG, et al. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial. BMJ Open. 2019;9:e034508. https:\/\/doi.org\/10.1136\/bmjopen-2019-034508.","journal-title":"BMJ Open"},{"key":"2787_CR16","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1248\/cpb.35.4907","volume":"35","author":"T Kakutani","year":"1987","unstructured":"Kakutani T, Atsumi R, Sumimoto E, Hashida M. Deconvolution analysis of the regeneration process of mitomycin C from prodrug in a muscle perfusion system based on statistical moment theory. Chem Pharm Bull. 1987;35:4907\u201314. https:\/\/doi.org\/10.1248\/cpb.35.4907.","journal-title":"Chem Pharm Bull"},{"key":"2787_CR17","doi-asserted-by":"publisher","first-page":"100526","DOI":"10.1016\/j.xcrm.2022.100526","volume":"3","author":"J Hendrikson","year":"2022","unstructured":"Hendrikson J, Liu Y, Ng WH, Lee JY, Lim AH, Loh JW, et al. Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis. Cell Rep Med. 2022;3:100526. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100526.","journal-title":"Cell Rep Med"},{"key":"2787_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nature10315","volume":"475","author":"G-W Li","year":"2011","unstructured":"Li G-W, Xie XS. Central dogma at the single-molecule level in living cells. Nature. 2011;475:308\u201315. https:\/\/doi.org\/10.1038\/nature10315.","journal-title":"Nature"},{"key":"2787_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature08987","volume":"464","author":"TJ Hudson","year":"2010","unstructured":"International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, et al. International network of cancer genome projects. Nature. 2010;464:993\u20138. https:\/\/doi.org\/10.1038\/nature08987.","journal-title":"Nature"},{"key":"2787_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45:1113\u201320. https:\/\/doi.org\/10.1038\/ng.2764.","journal-title":"Nat Genet"},{"key":"2787_CR21","doi-asserted-by":"publisher","first-page":"10051","DOI":"10.18632\/oncotarget.7067","volume":"7","author":"LGT Morris","year":"2016","unstructured":"Morris LGT, Riaz N, Desrichard A, \u015eenbabao\u011flu Y, Hakimi AA, Makarov V, et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget. 2016;7:10051\u201363. https:\/\/doi.org\/10.18632\/oncotarget.7067.","journal-title":"Oncotarget"},{"key":"2787_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/embor.2008.56","volume":"9","author":"EW Deutsch","year":"2008","unstructured":"Deutsch EW, Lam H, Aebersold R. PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO Rep. 2008;9:429\u201334. https:\/\/doi.org\/10.1038\/embor.2008.56.","journal-title":"EMBO Rep"},{"key":"2787_CR23","doi-asserted-by":"publisher","first-page":"D736","DOI":"10.1093\/nar\/gkp964","volume":"38","author":"JA Vizca\u00edno","year":"2010","unstructured":"Vizca\u00edno JA, C\u00f4t\u00e9 R, Reisinger F, Barsnes H, Foster JM, Rameseder J, et al. The Proteomics Identifications database: 2010 update. Nucleic Acids Res. 2010;38:D736\u201342. https:\/\/doi.org\/10.1093\/nar\/gkp964.","journal-title":"Nucleic Acids Res"},{"key":"2787_CR24","doi-asserted-by":"publisher","first-page":"283ra54","DOI":"10.1126\/scitranslmed.aaa1408","volume":"7","author":"N McGranahan","year":"2015","unstructured":"McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015;7:283ra54. https:\/\/doi.org\/10.1126\/scitranslmed.aaa1408.","journal-title":"Sci Transl Med"},{"key":"2787_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017;168:613\u201328. https:\/\/doi.org\/10.1016\/j.cell.2017.01.018.","journal-title":"Cell"},{"key":"2787_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:227\u201332. https:\/\/doi.org\/10.1038\/nrg3185.","journal-title":"Nat Rev Genet"},{"key":"2787_CR27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1074\/mcp.M112.024349","volume":"12","author":"W Albertin","year":"2013","unstructured":"Albertin W, Marullo P, Bely M, Aigle M, Bourgais A, Langella O, et al. Linking Post-Translational Modifications and Variation of Phenotypic Traits. Mol Cell Proteom. 2013;12:720\u201335. https:\/\/doi.org\/10.1074\/mcp.M112.024349.","journal-title":"Mol Cell Proteom"},{"key":"2787_CR28","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.21.02745","volume":"40","author":"YX Gwee","year":"2022","unstructured":"Gwee YX, Chia DKA, So J, Ceelen W, Yong WP, Tan P, et al. Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis. J Clin Oncol. 2022;40:2830\u201345. https:\/\/doi.org\/10.1200\/JCO.21.02745.","journal-title":"J Clin Oncol"},{"key":"2787_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1158\/2767-9764.CRC-23-0409","volume":"4","author":"E Sanz-Garcia","year":"2024","unstructured":"Sanz-Garcia E, Brown S, Lavery JA, Weiss J, Fuchs HE, Newcomb A, et al. Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry. Cancer Res Commun. 2024;4:475\u201386. https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0409.","journal-title":"Cancer Res Commun"},{"key":"2787_CR30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41467-023-36310-9","volume":"14","author":"X-Z Huang","year":"2023","unstructured":"Huang X-Z, Pang M-J, Li J-Y, Chen H-Y, Sun J-X, Song Y-X, et al. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis. Nat Commun. 2023;14:822. https:\/\/doi.org\/10.1038\/s41467-023-36310-9.","journal-title":"Nat Commun"},{"key":"2787_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature19949","volume":"537","author":"R Aebersold","year":"2016","unstructured":"Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016;537:347\u201355. https:\/\/doi.org\/10.1038\/nature19949.","journal-title":"Nature"},{"key":"2787_CR32","doi-asserted-by":"publisher","first-page":"100578","DOI":"10.1016\/j.mcpro.2023.100578","volume":"22","author":"L Qian","year":"2023","unstructured":"Qian L, Sun R, Xue Z, Guo T. Mass Spectrometry-Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective. Mol Cell Proteom. 2023;22:100578. https:\/\/doi.org\/10.1016\/j.mcpro.2023.100578.","journal-title":"Mol Cell Proteom"},{"key":"2787_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1021\/acs.jproteome.3c00591","volume":"23","author":"GS Omenn","year":"2024","unstructured":"Omenn GS, Lane L, Overall CM, Lindskog C, Pineau C, Packer NH, et al. The 2023 Report on the Proteome from the HUPO Human Proteome Project. J Proteome Res. 2024;23:532\u201349. https:\/\/doi.org\/10.1021\/acs.jproteome.3c00591.","journal-title":"J Proteome Res"},{"key":"2787_CR34","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1021\/acs.jproteome.4c00776","volume":"23","author":"GS Omenn","year":"2024","unstructured":"Omenn GS, Orchard S, Lane L, Lindskog C, Pineau C, Overall CM, et al. The 2024 Report on the Human Proteome from the HUPO Human Proteome Project. J Proteome Res. 2024;23:5296\u2013311. https:\/\/doi.org\/10.1021\/acs.jproteome.4c00776.","journal-title":"J Proteome Res"},{"key":"2787_CR35","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cell.2020.10.036","volume":"183","author":"K Krug","year":"2020","unstructured":"Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, et al. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell Elsevier BV. 2020;183:1436\u2013e145631. https:\/\/doi.org\/10.1016\/j.cell.2020.10.036.","journal-title":"Cell Elsevier BV"},{"key":"2787_CR36","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","volume":"184","author":"L Cao","year":"2021","unstructured":"Cao L, Huang C, Cui Zhou D, Hu Y, Lih TM, Savage SR, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell Elsevier BV. 2021;184:5031\u2013e505226. https:\/\/doi.org\/10.1016\/j.cell.2021.08.023.","journal-title":"Cell Elsevier BV"},{"key":"2787_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cell.2020.06.013","volume":"182","author":"MA Gillette","year":"2020","unstructured":"Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell Elsevier BV. 2020;182:200\u2013e22535. https:\/\/doi.org\/10.1016\/j.cell.2020.06.013.","journal-title":"Cell Elsevier BV"},{"key":"2787_CR38","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.cell.2020.10.044","volume":"183","author":"F Petralia","year":"2020","unstructured":"Petralia F, Tignor N, Reva B, Koptyra M, Chowdhury S, Rykunov D, et al. Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell Elsevier BV. 2020;183:1962.1985.e31. https:\/\/doi.org\/10.1016\/j.cell.2020.10.044.\u00a0","journal-title":"Cell Elsevier BV"},{"key":"2787_CR39","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1016\/j.cell.2021.07.016","volume":"184","author":"S Satpathy","year":"2021","unstructured":"Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, et al. A proteogenomic portrait of lung squamous cell carcinoma. Cell Elsevier BV. 2021;184:4348\u2013e437140. https:\/\/doi.org\/10.1016\/j.cell.2021.07.016.","journal-title":"Cell Elsevier BV"},{"key":"2787_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2021.01.004","volume":"184","author":"X Nie","year":"2021","unstructured":"Nie X, Qian L, Sun R, Huang B, Dong X, Xiao Q, et al. Multi-organ proteomic landscape of COVID-19 autopsies. Cell. 2021;184:775\u2013e79114. https:\/\/doi.org\/10.1016\/j.cell.2021.01.004.","journal-title":"Cell"},{"key":"2787_CR41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jmb.2005.07.038","volume":"352","author":"D Saerens","year":"2005","unstructured":"Saerens D, Pellis M, Loris R, Pardon E, Dumoulin M, Matagne A, et al. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol. 2005;352:597\u2013607. https:\/\/doi.org\/10.1016\/j.jmb.2005.07.038.","journal-title":"J Mol Biol"},{"key":"2787_CR42","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7:16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5.","journal-title":"Sci Rep"},{"key":"2787_CR43","doi-asserted-by":"publisher","first-page":"102646","DOI":"10.1016\/j.ctrv.2023.102646","volume":"121","author":"JM Berger","year":"2023","unstructured":"Berger JM, Preusser M, Berghoff AS, Bergen ES. Malignant ascites: Current therapy options and treatment prospects. Cancer Treat Rev. 2023;121:102646. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102646.","journal-title":"Cancer Treat Rev"},{"key":"2787_CR44","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1074\/mcp.M114.041194","volume":"13","author":"VO Shender","year":"2014","unstructured":"Shender VO, Pavlyukov MS, Ziganshin RH, Arapidi GP, Kovalchuk SI, Anikanov NA, et al. Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication. Mol Cell Proteom. 2014;13:3558\u201371. https:\/\/doi.org\/10.1074\/mcp.M114.041194.","journal-title":"Mol Cell Proteom"},{"key":"2787_CR45","doi-asserted-by":"publisher","first-page":"5484976","DOI":"10.1155\/2018\/5484976","volume":"2018","author":"J Zhang","year":"2018","unstructured":"Zhang J, Liang R, Wei J, Ye J, He Q, ChunlingYuan null, et al. Identification of Candidate Biomarkers in Malignant Ascites from Patients with Hepatocellular Carcinoma by iTRAQ-Based Quantitative Proteomic Analysis. Biomed Res Int. 2018;2018:5484976. https:\/\/doi.org\/10.1155\/2018\/5484976.","journal-title":"Biomed Res Int"},{"key":"2787_CR46","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.21873\/anticanres.15071","volume":"41","author":"F Kitamura","year":"2021","unstructured":"Kitamura F, Miyata T, Uemura N, Uchihara T, Imai K, Hayashi H, et al. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma. Anticancer Res. 2021;41:2895\u2013900. https:\/\/doi.org\/10.21873\/anticanres.15071.","journal-title":"Anticancer Res"},{"key":"2787_CR47","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523. https:\/\/doi.org\/10.1038\/s41467-019-09234-6.","journal-title":"Nat Commun"},{"key":"2787_CR48","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.it.2019.01.006","volume":"40","author":"F Mollinedo","year":"2019","unstructured":"Mollinedo F. Neutrophil Degranulation, Plasticity, and Cancer Metastasis. Trends Immunol. 2019;40:228\u201342. https:\/\/doi.org\/10.1016\/j.it.2019.01.006.","journal-title":"Trends Immunol"},{"key":"2787_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00357-014-9161-z","volume":"31","author":"F Murtagh","year":"2014","unstructured":"Murtagh F, Legendre P. Ward\u2019s Hierarchical Agglomerative Clustering Method: Which Algorithms Implement Ward\u2019s Criterion? J Classif. 2014;31:274\u201395. https:\/\/doi.org\/10.1007\/s00357-014-9161-z.","journal-title":"J Classif"},{"key":"2787_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00283","author":"A Appert-Collin","year":"2015","unstructured":"Appert-Collin A, Hubert P, Cr\u00e9mel G, Bennasroune A. Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol. 2015;6. https:\/\/doi.org\/10.3389\/fphar.2015.00283. Cited 4 Sept 2024.","journal-title":"Front Pharmacol [Internet]"},{"key":"2787_CR51","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1215\/15228517-2009-003","volume":"11","author":"F Perrone","year":"2009","unstructured":"Perrone F, Da Riva L, Orsenigo M, Losa M, Jocoll\u00e8 G, Millefanti C, et al. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol. 2009;11:725\u201336. https:\/\/doi.org\/10.1215\/15228517-2009-003.","journal-title":"Neuro Oncol"},{"key":"2787_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19:23\u201336. https:\/\/doi.org\/10.1038\/s41571-021-00549-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"2787_CR53","doi-asserted-by":"publisher","first-page":"e27633","DOI":"10.2196\/27633","volume":"23","author":"A L\u00e1nczky","year":"2021","unstructured":"L\u00e1nczky A, Gy\u0151rffy B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J Med Internet Res. 2021;23:e27633. https:\/\/doi.org\/10.2196\/27633.","journal-title":"J Med Internet Res"},{"key":"2787_CR54","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.7150\/jca.86568","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhou P, Liu M, Pei B. Expression And Prognostic Role of PRDX1 In Gastrointestinal Cancers. J Cancer. 2023;14:2895\u2013907. https:\/\/doi.org\/10.7150\/jca.86568.","journal-title":"J Cancer"},{"key":"2787_CR55","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","volume":"14","author":"BE Lippitz","year":"2013","unstructured":"Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14:e218\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(12)70582-X.","journal-title":"Lancet Oncol"},{"key":"2787_CR56","doi-asserted-by":"publisher","first-page":"101042832092452","DOI":"10.1177\/1010428320924524","volume":"42","author":"L Olsson","year":"2020","unstructured":"Olsson L, Lindmark G, Hammarstr\u00f6m M-L, Hammarstr\u00f6m S, Sitohy B. Evaluating macrophage migration inhibitory factor 1 expression as a prognostic biomarker in colon cancer. Tumour Biol. 2020;42:1010428320924524. https:\/\/doi.org\/10.1177\/1010428320924524.","journal-title":"Tumour Biol"},{"key":"2787_CR57","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.3390\/ijms19124122","volume":"19","author":"TM Noye","year":"2018","unstructured":"Noye TM, Lokman NA, Oehler MK, Ricciardelli C. S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer. Int J Mol Sci. 2018;19:4122. https:\/\/doi.org\/10.3390\/ijms19124122.","journal-title":"Int J Mol Sci"},{"key":"2787_CR58","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1158\/2159-8290.CD-23-1422","volume":"15","author":"S Cohen Shvefel","year":"2025","unstructured":"Cohen Shvefel S, Pai JA, Cao Y, Pal LR, Bartok O, Levy R, et al. Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma. Cancer Discov. 2025;15:553\u201377. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1422.","journal-title":"Cancer Discov"},{"key":"2787_CR59","doi-asserted-by":"publisher","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","volume":"52","author":"B Zdrazil","year":"2024","unstructured":"Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res. 2024;52:D1180\u201392. https:\/\/doi.org\/10.1093\/nar\/gkad1004.","journal-title":"Nucleic Acids Res"},{"key":"2787_CR60","doi-asserted-by":"publisher","first-page":"W612","DOI":"10.1093\/nar\/gkv352","volume":"43","author":"M Davies","year":"2015","unstructured":"Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, et al. ChEMBL web services: streamlining access to drug discovery data and utilities. Nucleic Acids Res. 2015;43:W612\u201320. https:\/\/doi.org\/10.1093\/nar\/gkv352.","journal-title":"Nucleic Acids Res"},{"key":"2787_CR61","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.celrep.2018.10.082","volume":"25","author":"MH Kubala","year":"2018","unstructured":"Kubala MH, Punj V, Placencio-Hickok VR, Fang H, Fernandez GE, Sposto R, et al. Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer. Cell Rep. 2018;25:2177\u2013e21917. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.082.","journal-title":"Cell Rep"},{"key":"2787_CR62","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish A, Tyler M, Greenwald AC, Hoefflin R, Simkin D, Tschernichovsky R, et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature. 2023;618:598\u2013606. https:\/\/doi.org\/10.1038\/s41586-023-06130-4.","journal-title":"Nature"},{"key":"2787_CR63","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C, et al. TGF-\u03b2 signaling in health, disease and therapeutics. Sig Transduct Target Ther. 2024;9:61. https:\/\/doi.org\/10.1038\/s41392-024-01764-w.","journal-title":"Sig Transduct Target Ther"},{"key":"2787_CR64","doi-asserted-by":"publisher","first-page":"e70580","DOI":"10.1002\/mco2.70580","volume":"7","author":"X Jin","year":"2026","unstructured":"Jin X, Wang J, Cao R, Jiang D. Wnt Signaling Pathway: Biological Function, Diseases, and Therapeutic Interventions. MedComm (2020). 2026;7:e70580. https:\/\/doi.org\/10.1002\/mco2.70580.","journal-title":"MedComm (2020)"},{"key":"2787_CR65","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/rme-2018-0073","volume":"13","author":"HE desJardins-Park","year":"2018","unstructured":"desJardins-Park HE, Foster DS, Longaker MT. Fibroblasts and Wound Healing: an Update. Regen Med. 2018;13:491\u20135. https:\/\/doi.org\/10.2217\/rme-2018-0073.","journal-title":"Regen Med"},{"key":"2787_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12392","volume":"43","author":"Z Fang","year":"2023","unstructured":"Fang Z, Meng Q, Xu J, Wang W, Zhang B, Liu J, et al. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. Cancer Commun. 2023;43:3\u201341. https:\/\/doi.org\/10.1002\/cac2.12392.","journal-title":"Cancer Commun"},{"key":"2787_CR67","unstructured":"Ong J. Proposed roles of PAI-1 and S100A10 in both the homeostatic and pathological states. Created in BioRender. 2025. https:\/\/BioRender.com\/h38fz6m."},{"key":"2787_CR68","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/s0969-2126(98)00064-1","volume":"6","author":"Y Xue","year":"1998","unstructured":"Xue Y, Bj\u00f6rquist P, Inghardt T, Linschoten M, Musil D, Sj\u00f6lin L, et al. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure. 1998;6:627\u201336. https:\/\/doi.org\/10.1016\/s0969-2126(98)00064-1.","journal-title":"Structure"},{"key":"2787_CR69","doi-asserted-by":"publisher","first-page":"622473","DOI":"10.3389\/fcvm.2020.622473","volume":"7","author":"M Sillen","year":"2020","unstructured":"Sillen M, Declerck PJ. Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. Front Cardiovasc Med. 2020;7:622473. https:\/\/doi.org\/10.3389\/fcvm.2020.622473.","journal-title":"Front Cardiovasc Med"},{"key":"2787_CR70","doi-asserted-by":"publisher","unstructured":"Placencio VR, Ichimura A, Miyata T, DeClerck YA. Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. Hsieh Y-H, editor. PLoS ONE. 2015;10:e0133786. https:\/\/doi.org\/10.1371\/journal.pone.0133786","DOI":"10.1371\/journal.pone.0133786"},{"key":"2787_CR71","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455\u201361. https:\/\/doi.org\/10.1002\/jcc.21334.","journal-title":"J Comput Chem"},{"key":"2787_CR72","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF, Forli S, AutoDock. Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model. 2021;61:3891\u20138. https:\/\/doi.org\/10.1021\/acs.jcim.1c00203.","journal-title":"J Chem Inf Model"},{"key":"2787_CR73","unstructured":"The PyMOL Molecular. Graphics System, Version 3.0 Schr\u00f6dinger, LLC."},{"key":"2787_CR74","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/j.1538-7836.2005.01311.x","volume":"3","author":"R Renckens","year":"2005","unstructured":"Renckens R, Roelofs JJTH, de Waard V, Florquin S, Lijnen HR, Carmeliet P, et al. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost. 2005;3:1018\u201325. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01311.x.","journal-title":"J Thromb Haemost"},{"key":"2787_CR75","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1152\/nips.01369.2001","volume":"17","author":"BR Binder","year":"2002","unstructured":"Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, et al. Plasminogen Activator Inhibitor 1: Physiological and Pathophysiological Roles. Physiology. 2002;17:56\u201361. https:\/\/doi.org\/10.1152\/nips.01369.2001.","journal-title":"Physiology"},{"key":"2787_CR76","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers13174318","volume":"13","author":"BP Rickard","year":"2021","unstructured":"Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, et al. Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. Cancers (Basel). 2021;13:4318. https:\/\/doi.org\/10.3390\/cancers13174318.","journal-title":"Cancers (Basel)"},{"key":"2787_CR77","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3389\/fonc.2019.01399","volume":"9","author":"D Aguilar-Cazares","year":"2019","unstructured":"Aguilar-Cazares D, Chavez-Dominguez R, Carlos-Reyes A, Lopez-Camarillo C, de la Hernadez ON, Lopez-Gonzalez JS. Contribution of Angiogenesis to Inflammation and Cancer. Front Oncol. 2019;9:1399. https:\/\/doi.org\/10.3389\/fonc.2019.01399.","journal-title":"Front Oncol"},{"key":"2787_CR78","doi-asserted-by":"publisher","first-page":"112153","DOI":"10.1016\/j.yexcr.2020.112153","volume":"394","author":"M Li","year":"2020","unstructured":"Li M, Wang J, Wang C, Xia L, Xu J, Xie X, et al. Microenvironment remodeled by tumor and stromal cells elevates fibroblast-derived COL1A1 and facilitates ovarian cancer metastasis. Exp Cell Res. 2020;394:112153. https:\/\/doi.org\/10.1016\/j.yexcr.2020.112153.","journal-title":"Exp Cell Res"},{"key":"2787_CR79","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/cells15090771","volume":"15","author":"S Sun","year":"2026","unstructured":"Sun S, Jia L, Yu Y, Jeong S-J, Zhang Y, Ryu D, et al. Rewiring Glycolysis in Cancer: From Tumor Initiation to Therapeutic Vulnerabilities. Cells. 2026;15:771. https:\/\/doi.org\/10.3390\/cells15090771.","journal-title":"Cells"},{"key":"2787_CR80","doi-asserted-by":"publisher","first-page":"218246","DOI":"10.1016\/j.canlet.2026.218246","volume":"644","author":"F Mokhles","year":"2026","unstructured":"Mokhles F, Moosavi MA, Gutierrez-Uzquiza A, Velasco G, Li M, Cordani M. Unraveling stress-adaptation pathways in cancer: Functional dissection through CRISPR-based genetic screens. Cancer Lett. 2026;644:218246. https:\/\/doi.org\/10.1016\/j.canlet.2026.218246.","journal-title":"Cancer Lett"},{"key":"2787_CR81","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1470-2045(01)00518-6","volume":"2","author":"G Nash","year":"2001","unstructured":"Nash G, Walsh D, Kakkar A. The role of the coagulation system in tumour angiogenesis. Lancet Oncol. 2001;2:608\u201313. https:\/\/doi.org\/10.1016\/S1470-2045(01)00518-6.","journal-title":"Lancet Oncol"},{"key":"2787_CR82","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182\u20136. https:\/\/doi.org\/10.1056\/NEJM197111182852108.","journal-title":"N Engl J Med"},{"key":"2787_CR83","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","volume":"79","author":"MS O\u2019Reilly","year":"1994","unstructured":"O\u2019Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315\u201328. https:\/\/doi.org\/10.1016\/0092-8674(94)90200-3.","journal-title":"Cell"},{"key":"2787_CR84","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/sj.embor.7400284","volume":"5","author":"MHVV Regenmortel","year":"2004","unstructured":"Regenmortel MHVV. Reductionism and complexity in molecular biology. EMBO Rep. 2004;5:1016\u201320. https:\/\/doi.org\/10.1038\/sj.embor.7400284.","journal-title":"EMBO Rep"},{"key":"2787_CR85","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/sj.embor.7401147","volume":"9","author":"F Mazzocchi","year":"2008","unstructured":"Mazzocchi F. Complexity in biology. Exceeding the limits of reductionism and determinism using complexity theory. EMBO Rep. 2008;9:10\u20134. https:\/\/doi.org\/10.1038\/sj.embor.7401147.","journal-title":"EMBO Rep"},{"key":"2787_CR86","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.neo.7900263","volume-title":"The hypercoagulable state of malignancy: pathogenesis and current debate","author":"GJ Caine","year":"2002","unstructured":"Caine GJ, Stonelake PS, Lip GYH, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Volume 4. New York, N.Y.: Neoplasia; 2002. pp. 465\u201373. https:\/\/doi.org\/10.1038\/sj.neo.7900263."},{"key":"2787_CR87","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.trecan.2021.12.008","volume":"8","author":"A Galmiche","year":"2022","unstructured":"Galmiche A, Rak J, Roumenina LT, Saidak Z. Coagulome and the tumor microenvironment: an actionable interplay. Trends Cancer. 2022;8:369\u201383. https:\/\/doi.org\/10.1016\/j.trecan.2021.12.008.","journal-title":"Trends Cancer"},{"key":"2787_CR88","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer Nat Publishing Group. 2020;123:9\u201316. https:\/\/doi.org\/10.1038\/s41416-020-0875-x.","journal-title":"Br J Cancer Nat Publishing Group"},{"key":"2787_CR89","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","volume":"13","author":"WH Gotlieb","year":"2012","unstructured":"Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13:154\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(11)70338-2.","journal-title":"Lancet Oncol"},{"key":"2787_CR90","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/IJWH.S29467","volume":"4","author":"RN Eskander","year":"2012","unstructured":"Eskander RN, Tewari KS. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health. 2012;4:395\u2013404. https:\/\/doi.org\/10.2147\/IJWH.S29467.","journal-title":"Int J Womens Health"},{"key":"2787_CR91","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/IGC.0000000000000286","volume":"24","author":"JS Berek","year":"2014","unstructured":"Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, et al. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014;24:1583\u20139. https:\/\/doi.org\/10.1097\/IGC.0000000000000286.","journal-title":"Int J Gynecol Cancer"},{"key":"2787_CR92","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","volume":"13","author":"A Burges","year":"2007","unstructured":"Burges A, Wimberger P, K\u00fcmper C, Gorbounova V, Sommer H, Schmalfeldt B, et al. Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM \u00d7 Anti-CD3 Antibody: A Phase I\/II Study. Clin Cancer Res. 2007;13:3899\u2013905. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2769.","journal-title":"Clin Cancer Res"},{"key":"2787_CR93","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11596-023-2753-2","volume":"43","author":"Y-N Li","year":"2023","unstructured":"Li Y-N, Li Y-Y, Wang S-X, Ma X-Y. Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study. Curr Med Sci. 2023;43:539\u201350. https:\/\/doi.org\/10.1007\/s11596-023-2753-2.","journal-title":"Curr Med Sci"},{"key":"2787_CR94","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/metabo13050618","volume":"13","author":"R Nadhan","year":"2023","unstructured":"Nadhan R, Kashyap S, Ha JH, Jayaraman M, Song YS, Isidoro C, et al. Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies. Metabolites. 2023;13:618. https:\/\/doi.org\/10.3390\/metabo13050618.","journal-title":"Metabolites"},{"key":"2787_CR95","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13045-022-01358-5","volume":"15","author":"X Zhong","year":"2022","unstructured":"Zhong X, He X, Wang Y, Hu Z, Huang H, Zhao S, et al. Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications. J Hematol Oncol. 2022;15:160. https:\/\/doi.org\/10.1186\/s13045-022-01358-5.","journal-title":"J Hematol Oncol"},{"key":"2787_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/2619526","volume":"2018","author":"S Su","year":"2018","unstructured":"Su S, Zheng G, Yin W, Liang Y, Liu Y, Song H, et al. Prognostic Significance of Blood, Serum, and Ascites Parameters in Patients with Malignant Peritoneal Mesothelioma or Peritoneal Carcinomatosis. Gastroenterol Res Pract. 2018;2018:1\u20138. https:\/\/doi.org\/10.1155\/2018\/2619526.","journal-title":"Gastroenterol Res Pract"},{"key":"2787_CR97","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1002\/cam4.1820","volume":"7","author":"Y Feng","year":"2018","unstructured":"Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y. Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018;7:6124\u201336. https:\/\/doi.org\/10.1002\/cam4.1820.","journal-title":"Cancer Med"},{"key":"2787_CR98","first-page":"228","volume":"22","author":"K Y\u00fcce","year":"2001","unstructured":"Y\u00fcce K, Baykal C, Gen\u00e7 C, Al A, Ayhan A. Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynaecol Oncol. 2001;22:228\u201332.","journal-title":"Eur J Gynaecol Oncol"},{"key":"2787_CR99","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.tibs.2018.01.006","volume":"43","author":"Z Lu","year":"2018","unstructured":"Lu Z, Hunter T. Metabolic Kinases Moonlighting as Protein Kinases. Trends Biochem Sci. 2018;43:301\u201310. https:\/\/doi.org\/10.1016\/j.tibs.2018.01.006.","journal-title":"Trends Biochem Sci"},{"key":"2787_CR100","doi-asserted-by":"publisher","first-page":"117863","DOI":"10.1016\/j.lfs.2020.117863","volume":"256","author":"Q Fu","year":"2020","unstructured":"Fu Q, Yu Z. Phosphoglycerate kinase 1 (PGK1) in cancer: A promising target for diagnosis and therapy. Life Sci. 2020;256:117863. https:\/\/doi.org\/10.1016\/j.lfs.2020.117863.","journal-title":"Life Sci"},{"key":"2787_CR101","doi-asserted-by":"publisher","first-page":"682461","DOI":"10.3389\/fonc.2021.682461","volume":"11","author":"R Gou","year":"2021","unstructured":"Gou R, Hu Y, Liu O, Dong H, Gao L, Wang S, et al. PGK1 Is a Key Target for Anti-Glycolytic Therapy of Ovarian Cancer: Based on the Comprehensive Analysis of Glycolysis-Related Genes. Front Oncol. 2021;11:682461. https:\/\/doi.org\/10.3389\/fonc.2021.682461.","journal-title":"Front Oncol"},{"key":"2787_CR102","first-page":"2263","volume":"17","author":"J Li","year":"2011","unstructured":"Li J, Riau AK, Setiawan M, Mehta JS, Ti S-E, Tong L, et al. S100A expression in normal corneal-limbal epithelial cells and ocular surface squamous cell carcinoma tissue. Mol Vis. 2011;17:2263\u201371.","journal-title":"Mol Vis"},{"key":"2787_CR103","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1007\/s13277-013-0962-1","volume":"34","author":"J Shang","year":"2013","unstructured":"Shang J, Zhang Z, Song W, Zhou B, Zhang Y, Li G, et al. S100A10 as a novel biomarker in colorectal cancer. Tumour Biol. 2013;34:3785\u201390. https:\/\/doi.org\/10.1007\/s13277-013-0962-1.","journal-title":"Tumour Biol"},{"key":"2787_CR104","first-page":"4343","volume":"26","author":"T Sakakibara","year":"2006","unstructured":"Sakakibara T, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, et al. PAI-1 expression levels in esophageal and colorectal cancers are closely correlated to those in corresponding normal tissues. Anticancer Res. 2006;26:4343\u20137.","journal-title":"Anticancer Res"},{"key":"2787_CR105","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41374-020-00512-2","volume":"101","author":"H Sakamoto","year":"2021","unstructured":"Sakamoto H, Koma Y-I, Higashino N, Kodama T, Tanigawa K, Shimizu M, et al. PAI-1 derived from cancer-associated fibroblasts in esophageal squamous cell carcinoma promotes the invasion of cancer cells and the migration of macrophages. Lab Invest. 2021;101:353\u201368. https:\/\/doi.org\/10.1038\/s41374-020-00512-2.","journal-title":"Lab Invest"},{"key":"2787_CR106","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3390\/ijms23010337","volume":"23","author":"AA Ismail","year":"2021","unstructured":"Ismail AA, Shaker BT, Bajou K. The Plasminogen-Activator Plasmin System in Physiological and Pathophysiological Angiogenesis. Int J Mol Sci. 2021;23:337. https:\/\/doi.org\/10.3390\/ijms23010337.","journal-title":"Int J Mol Sci"},{"key":"2787_CR107","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-15-0876","volume":"75","author":"VR Placencio","year":"2015","unstructured":"Placencio VR, DeClerck YA. Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. Cancer Res. 2015;75:2969\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0876.","journal-title":"Cancer Res"},{"key":"2787_CR108","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000175156","volume":"36","author":"B McMahon","year":"2008","unstructured":"McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb. 2008;36:184\u201394. https:\/\/doi.org\/10.1159\/000175156.","journal-title":"Pathophysiol Haemost Thromb"},{"key":"2787_CR109","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/ijc.2910600413","volume":"60","author":"G Liu","year":"1995","unstructured":"Liu G, Shuman MA, Cohen RL. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer. 1995;60:501\u20136. https:\/\/doi.org\/10.1002\/ijc.2910600413.","journal-title":"Int J Cancer"},{"key":"2787_CR110","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1160\/TH08-07-0427","volume":"100","author":"RD Balsara","year":"2008","unstructured":"Balsara RD, Ploplis VA. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost. 2008;100:1029\u201336.","journal-title":"Thromb Haemost"},{"key":"2787_CR111","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.ccell.2025.02.024","volume":"43","author":"Y-P Zhang","year":"2025","unstructured":"Zhang Y-P, Guo Z-Q, Cai X-T, Rong Z-X, Fang Y, Chen J-Q, et al. PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy. Cancer Cell. 2025;43:856\u2013e8749. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.024.","journal-title":"Cancer Cell"},{"key":"2787_CR112","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10555-019-09806-4","volume":"38","author":"MH Kubala","year":"2019","unstructured":"Kubala MH, DeClerck YA. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding. Cancer Metastasis Rev. 2019;38:483\u201392. https:\/\/doi.org\/10.1007\/s10555-019-09806-4.","journal-title":"Cancer Metastasis Rev"},{"key":"2787_CR113","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2741\/1529","volume":"10","author":"M Kwon","year":"2005","unstructured":"Kwon M, MacLeod TJ, Zhang Y, Waisman DM. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Front Biosci. 2005;10:300\u201325. https:\/\/doi.org\/10.2741\/1529.","journal-title":"Front Biosci"},{"key":"2787_CR114","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/pin.12861","volume":"69","author":"Y Saiki","year":"2019","unstructured":"Saiki Y, Horii A. Multiple functions of S100A10, an important cancer promoter. Pathol Int. 2019;69:629\u201336. https:\/\/doi.org\/10.1111\/pin.12861.","journal-title":"Pathol Int"},{"key":"2787_CR115","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1182\/blood-2011-05-353482","volume":"118","author":"AP Surette","year":"2011","unstructured":"Surette AP, Madureira PA, Phipps KD, Miller VA, Svenningsson P, Waisman DM. Regulation of fibrinolysis by S100A10 in vivo. Blood. 2011;118:3172\u201381. https:\/\/doi.org\/10.1182\/blood-2011-05-353482.","journal-title":"Blood"},{"key":"2787_CR116","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1016\/j.febslet.2013.08.012","volume":"587","author":"HK Myrvang","year":"2013","unstructured":"Myrvang HK, Guo X, Li C, Dekker LV. Protein interactions between surface annexin A2 and S100A10 mediate adhesion of breast cancer cells to microvascular endothelial cells. FEBS Lett. 2013;587:3210\u20135. https:\/\/doi.org\/10.1016\/j.febslet.2013.08.012.","journal-title":"FEBS Lett"},{"key":"2787_CR117","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.1158\/0008-5472.CAN-11-1748","volume":"71","author":"KD Phipps","year":"2011","unstructured":"Phipps KD, Surette AP, O\u2019Connell PA, Waisman DM. Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Cancer Res. 2011;71:6676\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1748.","journal-title":"Cancer Res"},{"key":"2787_CR118","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2217\/fon.12.67","volume":"8","author":"PA O\u2019Connell","year":"2012","unstructured":"O\u2019Connell PA, Waisman DM. Regulation of plasmin generation by the annexin A2 heterotetramer: a shift in perspective. Future Oncol Lond Engl. 2012;8:763\u20135. https:\/\/doi.org\/10.2217\/fon.12.67.","journal-title":"Future Oncol Lond Engl"},{"key":"2787_CR119","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13048-019-0592-3","volume":"12","author":"L Wang","year":"2019","unstructured":"Wang L, Yan W, Li X, Liu Z, Tian T, Chen T, et al. S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin. J Ovarian Res. 2019;12:113. https:\/\/doi.org\/10.1186\/s13048-019-0592-3.","journal-title":"J Ovarian Res"},{"key":"2787_CR120","doi-asserted-by":"publisher","first-page":"559486","DOI":"10.3389\/fcell.2020.559486","volume":"8","author":"Y Li","year":"2020","unstructured":"Li Y, Li X-Y, Li L-X, Zhou R-C, Sikong Y, Gu X, et al. S100A10 Accelerates Aerobic Glycolysis and Malignant Growth by Activating mTOR-Signaling Pathway in Gastric Cancer. Front Cell Dev Biol. 2020;8:559486. https:\/\/doi.org\/10.3389\/fcell.2020.559486.","journal-title":"Front Cell Dev Biol"},{"key":"2787_CR121","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3892\/ol.2018.9751","volume":"17","author":"NA Tantyo","year":"2019","unstructured":"Tantyo NA, Karyadi AS, Rasman SZ, Salim MRG, Devina A, Sumarpo A. The prognostic value of S100A10 expression in cancer. Oncol Lett. 2019;17:1417\u201324. https:\/\/doi.org\/10.3892\/ol.2018.9751.","journal-title":"Oncol Lett"},{"key":"2787_CR122","doi-asserted-by":"publisher","first-page":"1150991","DOI":"10.3389\/fcell.2023.1150991","volume":"11","author":"TE Kelly","year":"2023","unstructured":"Kelly TE, Spillane CL, Ward MP, Hokamp K, Huang Y, Tewari P, et al. Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy. Front Cell Dev Biol. 2023;11:1150991. https:\/\/doi.org\/10.3389\/fcell.2023.1150991.","journal-title":"Front Cell Dev Biol"},{"key":"2787_CR123","doi-asserted-by":"publisher","first-page":"11650","DOI":"10.1038\/s41598-020-68535-9","volume":"10","author":"M Bydoun","year":"2020","unstructured":"Bydoun M, Sterea A, Weaver ICG, Bharadwaj AG, Waisman DM. Author Correction: A novel mechanism of plasminogen activation in epithelial and mesenchymal cells. Sci Rep. 2020;10:11650. https:\/\/doi.org\/10.1038\/s41598-020-68535-9.","journal-title":"Sci Rep"},{"key":"2787_CR124","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41576-020-0258-4","volume":"21","author":"C Buccitelli","year":"2020","unstructured":"Buccitelli C, Selbach M. mRNAs, proteins and the emerging principles of gene expression control. Nat Rev Genet. 2020;21:630\u201344. https:\/\/doi.org\/10.1038\/s41576-020-0258-4.","journal-title":"Nat Rev Genet"},{"key":"2787_CR125","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ijc.2910600505","volume":"60","author":"E Bianchi","year":"1995","unstructured":"Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA, Smith HS. Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer. 1995;60:597\u2013603. https:\/\/doi.org\/10.1002\/ijc.2910600505.","journal-title":"Int J Cancer"},{"key":"2787_CR126","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.2217\/fon.14.163","volume":"10","author":"M Bydoun","year":"2014","unstructured":"Bydoun M, Waisman DM. On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity. Future Oncol. 2014;10:2469\u201379. https:\/\/doi.org\/10.2217\/fon.14.163.","journal-title":"Future Oncol"},{"key":"2787_CR127","unstructured":"Ong C-AJ, Teo CCM, Chia CS, Tan GHC, Tan SQX, Hendrikson J et al. Biomarker with therapeutic implications for peritoneal carcinomatosis. https:\/\/patentimages.storage.googleapis.com\/5e\/ca\/71\/f4964a40bbfaa5\/US20220170940A1.pdf."},{"key":"2787_CR128","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2217\/fon.10.100","volume":"6","author":"Z Lu","year":"2010","unstructured":"Lu Z, Wang J, Wientjes MG, Au JL-S. Intraperitoneal therapy for peritoneal cancer. Future Oncol Lond Engl. 2010;6:1625\u201341. https:\/\/doi.org\/10.2217\/fon.10.100.","journal-title":"Future Oncol Lond Engl"},{"key":"2787_CR129","doi-asserted-by":"publisher","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","volume":"288","author":"MF Flessner","year":"2005","unstructured":"Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Ren Physiol. 2005;288:F433\u2013442. https:\/\/doi.org\/10.1152\/ajprenal.00313.2004.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2787_CR130","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume-title":"Peritoneal Carcinomatosis: Principles of Management [Internet]","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. In: Sugarbaker PH, editor. Peritoneal Carcinomatosis: Principles of Management [Internet]. Boston, MA: Springer US; 1996. pp. 53\u201363. [cited 2020 Oct 6]. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_4."},{"key":"2787_CR131","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","volume":"15","author":"M Babamohamadi","year":"2024","unstructured":"Babamohamadi M, Mohammadi N, Faryadi E, Haddadi M, Merati A, Ghobadinezhad F, et al. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy. Cell Death Dis. 2024;15:17. https:\/\/doi.org\/10.1038\/s41419-023-06391-x.","journal-title":"Cell Death Dis"},{"key":"2787_CR132","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1756-9966-32-60","volume":"32","author":"F Ren","year":"2013","unstructured":"Ren F, Shi H, Zhang G, Zhang R. Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance. J Exp Clin Cancer Res. 2013;32:60. https:\/\/doi.org\/10.1186\/1756-9966-32-60.","journal-title":"J Exp Clin Cancer Res"},{"key":"2787_CR133","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0002-9440(10)64637-8","volume":"157","author":"E Dublin","year":"2000","unstructured":"Dublin E, Hanby A, Patel NK, Liebman R, Barnes D. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol. 2000;157:1219\u201327. https:\/\/doi.org\/10.1016\/S0002-9440(10)64637-8.","journal-title":"Am J Pathol"},{"key":"2787_CR134","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.3390\/ijms22052721","volume":"22","author":"M Sillen","year":"2021","unstructured":"Sillen M, Declerck PJ. A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target? Int J Mol Sci. 2021;22:2721. https:\/\/doi.org\/10.3390\/ijms22052721.","journal-title":"Int J Mol Sci"},{"key":"2787_CR135","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/cells9051071","volume":"9","author":"S Mu\u00f1oz-Galv\u00e1n","year":"2020","unstructured":"Mu\u00f1oz-Galv\u00e1n S, Rivero M, Peinado-Serrano J, Martinez-P\u00e9rez J, Fern\u00e1ndez-Fern\u00e1ndez M, Jos\u00e9 Ortiz M, et al. PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208. Cells. 2020;9:1071. https:\/\/doi.org\/10.3390\/cells9051071.","journal-title":"Cells"},{"key":"2787_CR136","doi-asserted-by":"publisher","first-page":"57351","DOI":"10.18632\/oncotarget.10344","volume":"7","author":"MA Pav\u00f3n","year":"2016","unstructured":"Pav\u00f3n MA, Arroyo-Solera I, C\u00e9spedes MV, Casanova I, Le\u00f3n X, Mangues R. uPA\/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. Oncotarget. 2016;7:57351\u201366. https:\/\/doi.org\/10.18632\/oncotarget.10344.","journal-title":"Oncotarget"},{"key":"2787_CR137","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S0959-8049(98)00029-X","volume":"34","author":"P Strojan","year":"1998","unstructured":"Strojan P, Budihna M, \u0160mid L, Vrhovec I, \u0160krk J. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur J Cancer. 1998;34:1193\u20137. https:\/\/doi.org\/10.1016\/S0959-8049(98)00029-X.","journal-title":"Eur J Cancer"},{"key":"2787_CR138","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0304-3835(99)00376-6","volume":"150","author":"SY Rha","year":"2000","unstructured":"Rha SY, Yang WI, Gong SJ, Kim JJ, Yoo NC, Roh JK, et al. Correlation of tissue and blood plasminogen activation system in breast cancer. Cancer Lett. 2000;150:137\u201345. https:\/\/doi.org\/10.1016\/S0304-3835(99)00376-6.","journal-title":"Cancer Lett"},{"key":"2787_CR139","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.tranon.2015.05.002","volume":"8","author":"R Divella","year":"2015","unstructured":"Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, et al. Circulating Levels of PAI-1 and SERPINE1 4G\/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE. Translational Oncol. 2015;8:273\u20138. https:\/\/doi.org\/10.1016\/j.tranon.2015.05.002.","journal-title":"Translational Oncol"},{"key":"2787_CR140","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-019-0979-8","volume":"567","author":"X Liu","year":"2019","unstructured":"Liu X, Wang Y, Lu H, Li J, Yan X, Xiao M, et al. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature. 2019;567:525\u20139. https:\/\/doi.org\/10.1038\/s41586-019-0979-8.","journal-title":"Nature"},{"key":"2787_CR141","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, L\u00f3pez-Moyado IF, Seo H, Lio C-WJ, Hempleman LJ, Sekiya T, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567:530\u20134. https:\/\/doi.org\/10.1038\/s41586-019-0985-x.","journal-title":"Nature"},{"key":"2787_CR142","doi-asserted-by":"publisher","first-page":"624122","DOI":"10.3389\/fendo.2020.624122","volume":"11","author":"L Odagiu","year":"2020","unstructured":"Odagiu L, May J, Boulet S, Baldwin TA, Labrecque N. Role of the Orphan Nuclear Receptor NR4A Family in T-Cell Biology. Front Endocrinol (Lausanne). 2020;11:624122. https:\/\/doi.org\/10.3389\/fendo.2020.624122.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02787-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02787-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02787-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:02:06Z","timestamp":1790262126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02787-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":142,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2787"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02787-3","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All recruited patients provided written informed consent according to the approved protocols by the SingHealth Centralized Institutional Review Board (CIRB Ref: 2015\/2479, 2015\/3019, 2018\/3046 and 2020\/2145).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"225"}}